P53 acetylation: Regulation and consequences

Cancers

Volumn 7, Issue 1, 2014, Pages 30-69

  Reed, Sara M ^a,b   Quelle, Dawn E ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b The University of Iowa   (United States)

Author keywords

Acetylation; Histone acetyltransferases (HATs); MOF; MOZ); MYST family HATs (Tip60; P300 CBP; P53; PCAF; Post translational modifications; Transcription; Tumor suppression

Indexed keywords

ACYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; LYSINE; MEMBRANE PROTEIN; PROTEIN MOF; PROTEIN MOZ; PROTEIN P53; PROTEIN TIP60; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING AFFINITY; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL FATE; CELL STRESS; CELLULAR DISTRIBUTION; DEACETYLATION; GENE TARGETING; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PERSONALIZED MEDICINE; PROTEIN ACETYLATION; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

EID: 84920875263     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7010030     Document Type: Review

References (264)

1. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. Cell2009, 137, 413–431.
2. Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer2009, 9, 749–758.
3. Janus, F.; Albrechtsen, N.; Knippschild, U.; Wiesmuller, L.; Grosse, F.; Deppert, W. Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding. Mol. Cell. Biol. 1999, 19, 2155–2168.
4. Vaseva, A.V.; Moll, U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta-Bioenerg. 2009, 1787, 414–420.
5. Green, D.R.; Kroemer, G. Cytoplasmic functions of the tumour suppressor p53. Nature2009, 458, 1127–1130.
6. Godefroy, N.; Lemaire, C.; Renaud, F.; Rincheval, V.; Perez, S.; Parvu-Ferecatu, I.; Mignotte, B.; Vayssiere, J.L. p53 Can promote mitochondria- and caspase-independent apoptosis. Cell Death Differ. 2004, 11, 785–787.
7. Leu, J.I.J.; Dumont, P.; Hafey, M.; Murphy, M.E.; George, D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6, 443–450.
8. El-Deiry, W.S. Regulation of p53 downstream genes. Sem. Cancer Biol. 1998, 8, 345–357.
9. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell. Biol. 2008, 9, 402–412.
10. Xue, W.; Zender, L.; Miething, C.; Dickins, R.A.; Hernando, E.; Krizhanovsky, V.; Cordon-Cardo, C.; Lowe, S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature2007, 445, 656–660.
11. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature2007, 445, 661–665.
12. Lane, D.P. p53, Guardian of the genome. Nature1992, 358, 15–16.
13. Jiang, D.; Attardi, L.D. Engaging the p53 metabolic brake drives senescence. Cell Res. 2013, 23, 739–740.
14. Hock, A.K.; Vousden, K.H. Tumor suppression by p53: Fall of the triumvirate? Cell2012, 149, 1183–1185.
15. Moll, U.M.; Wolff, S.; Speidel, D.; Deppert, W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 2005, 17, 631–636.
16. Jiang, D.; Brady, C.A.; Johnson, T.M.; Lee, E.Y.; Park, E.J.; Scott, M.P.; Attardi, L.D. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl. Acad. Sci. USA2011, 108, 17123–17128.
17. Brady, C.A.; Jiang, D.; Mello, S.S.; Johnson, T.M.; Jarvis, L.A.; Kozak, M.M.; Broz, D.K.; Basak, S.; Park, E.J.; McLaughlin, M.E.; et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell2011, 145, 571–583.
18. Donehower, L.A.; Harvey, M.; Slagle, B.L.; McArthur, M.J.; Montgomery, C.A., Jr.; Butel, J.S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature1992, 356, 215–221.
19. Jacks, T.; Remington, L.; Williams, B.O.; Schmitt, E.M.; Halachmi, S.; Bronson, R.T.; Weinberg, R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4, 1–7.
20. Olive, K.P.; Tuveson, D.A.; Ruhe, Z.C.; Yin, B.; Willis, N.A.; Bronson, R.T.; Crowley, D.; Jacks, T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell2004, 119, 847–860.
21. Garcia, P.B.; Attardi, L.D. Illuminating p53 function in cancer with genetically engineered mouse models. Sem. Cell Dev. Biol. 2014, doi:10.1016/j.semcdb.2013.12.014.
22. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature2000, 408, 307–310.
23. Lowe, S.W.; Sherr, C.J. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 2003, 13, 77–83.
24. Petitjean, A.; Achatz, M.I.W.; Borresen-Dale, A.L.; Hainaut, P.; Olivier, M. Tp53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene2007, 26, 2157–2165.
25. Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, doi:10.1101/cshperspect.a001008.
26. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer2009, 9, 862–873.
27. Nichols, K.E.; Malkin, D.; Garber, J.E.; Fraumeni, J.F.; Li, F.P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomark. Prev. 2001, 10, 83–87.
28. Chen, F.; Wang, W.; El-Deiry, W.S. Current strategies to target p53 in cancer. Biochem. Pharmacol. 2010, 80, 724–730.
29. Lane, D.P.; Cheok, C.F.; Lain, S. p53-Based cancer therapy. Cold Spring Harb. Perspect. Biol. 2010, doi:10.1101/cshperspect.a001222.
30. Cheok, C.F.; Verma, C.S.; Baselga, J.; Lane, D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8, 25–37.
31. Meek, D.W.; Anderson, C.W. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 2009, doi:10.1101/cshperspect.a000950.
32. Kruse, J.-P.; Gu, W. Modes of p53 regulation. Cell2009, 137, 609–622.
33. Lee, J.T.; Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17, 86–92.
34. Lee, S.W.; Seong, M.W.; Jeon, Y.J.; Chung, C.H. Ubiquitin E3 ligases controlling p53 stability. Anim. Cells Syst. 2012, 16, 173–182.
35. Allfrey, V.G.; Faulkner, R.; Mirsky, A.E. Acetylation and methylation of histones and their possible role in regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA1964, 51, 786–794.
36. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature1997, 389, 349–352.
37. Swygert, S.G.; Peterson, C.L. Chromatin dynamics: Interplay between remodeling enzymes and histone modifications. Biochim. Biophys. Acta2014, 1839, 728–736.
38. Gu, W.; Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell1997, 90, 595–606.
39. Ito, A.; Lai, C.H.; Zhao, X.; Saito, S.; Hamilton, M.H.; Appella, E.; Yao, T.P. p300/CBP-Mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by Mdm2. EMBO J. 2001, 20, 1331–1340.
40. Tang, Y.; Zhao, W.; Chen, Y.; Zhao, Y.; Gu, W. Acetylation is indispensable for p53 activation. Cell2008, 133, 612–626.
41. Munoz-Fontela, C.; Gonzalez, D.; Marcos-Villar, L.; Campagna, M.; Gallego, P.; Gonzalez-Santamaria, J.; Herranz, D.; Gu, W.; Serrano, M.; Aaronson, S.A.; et al. Acetylation is indispensable for p53 antiviral activity. Cell Cycle2011, 10, 3701–3705.
42. Pearson, M.; Carbone, R.; Sebastiani, C.; Cioce, M.; Fagioli, M.; Saito, S.; Higashimoto, Y.; Appella, E.; Minucci, S.; Pandolfi, P.P.; et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature2000, 406, 207–210.
43. Feng, L.J.; Lin, T.X.; Uranishi, H.; Gu, W.; Xu, Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 2005, 25, 5389–5395.
44. Krummel, K.A.; Lee, C.J.; Toledo, F.; Wahl, G.M. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA2005, 102, 10188–10193.
45. Brooks, C.; Gu, W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell2011, 2, 456–462.
46. Marouco, D.; Garabadgiu, A.V.; Melino, G.; Barlev, N.A. Lysine-specific modifications of p53: A matter of life and death? Oncotarget2013, 4, 1556–1571.
47. Benkirane, M.; Sardet, C.; Coux, O. Lessons from interconnected ubiquitylation and acetylation of p53: Think metastable networks. Biochem. Soc. Trans. 2010, 38, 98–103.
48. Avantaggiati, M.L.; Ogryzko, V.; Gardner, K.; Giordano, A.; Levine, A.S.; Kelly, K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell1997, 89, 1175–1184.
49. Lill, N.L.; Grossman, S.R.; Ginsberg, D.; DeCaprio, J.; Livingston, D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature1997, 387, 823–827.
50. Luo, J.Y.; Li, M.Y.; Tang, Y.; Laszkowska, M.; Roeder, R.G.; Gu, W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl. Acad. Sci. USA2004, 101, 2259–2264.
51. Sakaguchi, K.; Herrera, J.E.; Saito, S.; Miki, T.; Bustin, M.; Vassilev, A.; Anderson, C.W.; Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12, 2831–2841.
52. Lane, D.P.; Madhumalar, A.; Lee, A.P.; Tay, B.-H.; Verma, C.; Brenner, S.; Venkatesh, B. Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Cell Cycle2011, 10, 4272–4279.
53. Wang, Y.H.; Tsay, Y.G.; Tan, B.C.M.; Lo, W.Y.; Lee, S.C. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J. Biol. Chem. 2003, 278, 25568–25576.
54. Liu, L.; Scolnick, D.M.; Trievel, R.C.; Zhang, H.B.; Marmorstein, R.; Halazonetis, T.D.; Berger, S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 1999, 19, 1202–1209.
55. Prives, C.; Manley, J.L. Why is p53 acetylated? Cell2001, 107, 815–818.
56. Snowden, A.W.; Perkins, N.D. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem. Pharmacol. 1998, 55, 1947–1954.
57. Chan, H.M.; la Thangue, N.B. p300/CBP Proteins: Hats for transcriptional bridges and scaffolds. J. Cell Sci. 2001, 114, 2363–2373.
58. Arany, Z.; Sellers, W.R.; Livingston, D.M.; Eckner, R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell1994, 77, 799–800.
59. Bannister, A.J.; Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature1996, 384, 641–643.
60. Ogryzko, V.V.; Schiltz, R.L.; Russanova, V.; Howard, B.H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell1996, 87, 953–959.
61. Buschmann, T.; Adler, V.; Matusevich, E.; Fuchs, S.Y.; Ronai, Z. p53 phosphorylation and association with Murine double minute 2, c-Jun NH2-terminal kinase, p14(ARF), and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res. 2000, 60, 896–900.
62. Wadgaonkar, R.; Phelps, K.M.; Haque, Z.; Williams, A.J.; Silverman, E.S.; Collins, T. CREB-binding protein is a nuclear integrator of nuclear factor-kappa B and p53 signaling. J. Biol. Chem. 1999, 274, 1879–1882.
63. Scolnick, D.M.; Chehab, N.H.; Stavridi, E.S.; Lien, M.C.; Caruso, L.; Moran, E.; Berger, S.L.; Halazonetis, T.D. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997, 57, 3693–3696.
64. Grossman, S.R.; Perez, M.; Kung, A.L.; Joseph, M.; Mansur, C.; Ziao, Z.X.; Kumar, S.; Howley, P.M.; Livingston, D.M. p300/Mdm2 complexes participate in Mdm2-mediated p53 degradation. Mol. Cell1998, 2, 405–415.
65. Gu, W.; Shi, X.-L.; Roeder, R.G. Synergistic activation of transcription by CBP and p53. Nature1997, 387, 819–823.
66. Barlev, N.A.; Liu, L.; Chehab, N.H.; Mansfield, K.; Harris, K.G.; Halazonetis, T.D.; Berger, S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell2001, 8, 1243–1254.
67. Iyer, N.G.; Chin, S.F.; Ozdag, H.; Daigo, Y.; Hu, D.E.; Cariati, M.; Brindle, K.; Aparicio, S.; Caldas, C. p300 Regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl. Acad. Sci. USA2004, 101, 7386–7391.
68. Yuan, Z.M.; Huang, Y.Y.; Ishiko, T.; Nakada, S.; Utsugisawa, T.; Shioya, H.; Utsugisawa, Y.; Yokoyama, K.; Weichselbaum, R.; Shi, Y.; et al. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 1999, 274, 1883–1886.
69. Romanov, V.S.; Abramova, M.V.; Svetlikova, S.B.; Bykova, T.V.; Zubova, S.G.; Aksenov, N.D.; Fornace, A.J., Jr.; Pospelova, T.V.; Pospelov, V.A. p21(waf1) Is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle2010, 9, 3945–3955.
70. Sherr, C.J.; Roberts, J.M. CDK inhibitors: Positive and negative regulators of G(1)-phase progression. Genes Dev. 1999, 13, 1501–1512.
71. Kasper, L.H.; Thomas, M.C.; Zambetti, G.P.; Brindle, P.K. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways. Cell Cycle2011, 10, 212–221.
72. Brochier, C.; Dennis, G.; Rivieccio, M.A.; McLaughlin, K.; Coppola, G.; Ratan, R.R.; Langley, B. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J. Neurosci. 2013, 33, 8621–8632.
73. Yang, X.J.; Ogryzko, V.V.; Nishikawa, J.; Howard, B.H.; Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature1996, 382, 319–324.
74. Knights, C.D.; Catania, J.; di Giovanni, S.; Muratoglu, S.; Perez, R.; Swartzbeck, A.; Quong, A.A.; Zhang, X.J.; Beerman, T.; Pestell, R.G.; et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 2006, 173, 533–544.
75. Chao, C.; Wu, Z.; Mazur, S.J.; Borges, H.; Rossi, M.; Lin, T.; Wang, J.Y.J.; Anderson, C.W.; Appella, E.; Xu, Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 2006, 26, 6859–6869.
76. Love, I.M.; Sekaric, P.; Shi, D.; Grossman, S.R.; Androphy, E.J. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle2012, 11, 2458–2466.
77. Tang, Y.; Luo, J.; Zhang, W.; Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell2006, 24, 827–839.
78. Sykes, S.M.; Mellert, H.S.; Holbert, M.A.; Li, K.; Marmorstein, R.; Lane, W.S.; McMahon, S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell2006, 24, 841–851.
79. Mellert, H.; Sykes, S.M.; Murphy, M.E.; McMahon, S.B. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle2007, 6, 1304–1306.
80. Deissler, H.; Kafka, A.; Schuster, E.; Sauer, G.; Kreienberg, R.; Zeillinger, R. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol. Rep. 2004, 11, 1281–1286.
81. Hashimoto, T.; Tokuchi, Y.; Hayashi, M.; Kobayashi, Y.; Nishida, K.; Hayashi, S.; Ishikawa, Y.; Tsuchiya, S.; Nakagawa, K.; Hayashi, J.; et al. p53 Null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 1999, 59, 5572–5577.
82. Hayes, V.M.; Dirven, C.M.F.; Dam, A.; Verlind, E.; Molenaar, W.M.; Mooij, J.J.A.; Hofstra, R.M.W.; Buys, C. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol. 1999, 9, 463–467.
83. Leitao, M.M.; Soslow, R.A.; Baergen, R.N.; Olvera, N.; Arroyo, C.; Boyd, J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 2004, 93, 301–306.
84. Meyers, F.J.; Chi, S.G.; Fishman, J.R.; White, R.W.D.; Gumerlock, P.H. p53 Mutations in benign prostatic hyperplasia. J. Natl. Cancer Inst. 1993, 85, 1856–1858.
85. Rokudai, S.; Laptenko, O.; Arnal, S.M.; Taya, Y.; Kitabayashi, I.; Prives, C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc. Natl. Acad. Sci. USA2013, 110, 3895–3900.
86. Squatrito, M.; Gorrini, C.; Amati, B. Tip60 in DNA damage response and growth control: Many tricks in one hat. Trends Cell Biol. 2006, 16, 433–442.
87. Berns, K.; Hijmans, E.M.; Mullenders, J.; Brummelkamp, T.R.; Velds, A.; Heimerikx, M.; Kerkhoven, R.M.; Madiredjo, M.; Nijkamp, W.; Weigelt, B.; et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature2004, 428, 431–437.
88. Legube, G.; Linares, L.K.; Tyteca, S.; Caron, C.; Scheffner, M.; Chevillard-Briet, M.; Trouche, D. Role of the histone acetyl transferase Tip60 in the p53 pathway. J. Biol. Chem. 2004, 279, 44825–44833.
89. Dohmesen, C.; Koeppel, M.; Dobbelstein, M. Specific inhibition of Mdm2-mediated neddylation by Tip60. Cell Cycle2008, 7, 222–231.
90. Legube, G.; Linares, L.K.; Lemercier, C.; Scheffner, M.; Khochbin, S.; Trouche, D. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 2002, 21, 1704–1712.
91. Xirodimas, D.P.; Saville, M.K.; Bourdon, J.C.; Hay, R.T.; Lane, D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell2004, 118, 83–97.
92. Liu, N.; Wang, J.; Wang, J.; Wang, R.; Liu, Z.; Yu, Y.; Lu, H. ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer Res. 2013, 73, 3749–3760.
93. Arbely, E.; Natan, E.; Brandt, T.; Allen, M.D.; Veprintsev, D.B.; Robinson, C.V.; Chin, J.W.; Joerger, A.C.; Fersht, A.R. Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc. Natl. Acad. Sci. USA2011, 108, 8251–8256.
94. Li, X.; Wu, L.; Corsa, C.A.S.; Kunkel, S.; Dou, Y. Two mammalian mof complexes regulate transcription activation by distinct mechanisms. Mol. Cell2009, 36, 290–301.
95. Hilfiker, A.; HilfikerKleiner, D.; Pannuti, A.; Lucchesi, J.C. MOF, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J. 1997, 16, 2054–2060.
96. Akhtar, A.; Becker, P.B. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol. Cell2000, 5, 367–375.
97. Taipale, M.; Rea, S.; Richter, K.; Vilar, A.; Lichter, P.; Imhof, A.; Akhtar, A. HMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol. Cell. Biol. 2005, 25, 6798–6810.
98. Smith, E.R.; Pannuti, A.; Gu, W.G.; Steurnagel, A.; Cook, R.G.; Allis, C.D.; Lucchesi, J.C. The Drosophila MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. Mol. Cell. Biol. 2000, 20, 312–318.
99. Smith, E.R.; Cayrou, C.; Huang, R.; Lane, W.S.; Cote, J.; Lucchesi, J.C. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol. Cell. Biol. 2005, 25, 9175–9188.
100. Dou, Y.L.; Milne, T.A.; Tackett, A.J.; Smith, E.R.; Fukuda, A.; Wysocka, J.; Allis, C.D.; Chait, B.T.; Hess, J.L.; Roeder, R.G. Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF. Cell2005, 121, 873–885.
101. Katsumoto, T.; Yoshida, N.; Kitabayashi, I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 2008, 99, 1523–1527.
102. Rokudai, S.; Aikawa, Y.; Tagata, Y.; Tsuchida, N.; Taya, Y.; Kitabayashi, I. Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J. Biol. Chem. 2009, 284, 237–244.
103. Luo, J.Y.; Su, F.; Chen, D.L.; Shiloh, A.; Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature2000, 408, 377–381.
104. Luo, J.Y.; Nikolaev, A.Y.; Imai, S.; Chen, D.L.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by SIR2 alpha promotes cell survival under stress. Cell2001, 107, 137–148.
105. Vaziri, H.; Dessain, S.K.; Eagon, E.N.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. hSIR2(SIRT1) Functions as an NAD-dependent p53 deacetylase. Cell2001, 107, 149–159.
106. Ito, A.; Kawaguchi, Y.; Lai, C.H.; Kovacs, J.J.; Higashimoto, Y.; Appella, E.; Yao, T.P. Mdm2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21, 6236–6245.
107. Li, M.Y.; Luo, J.Y.; Brooks, C.L.; Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 2002, 277, 50607–50611.
108. Juan, L.J.; Shia, W.J.; Chen, M.H.; Yang, W.M.; Seto, E.; Lin, Y.S.; Wu, C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275, 20436–20443.
109. Ding, G.; Liu, H.-D.; Huang, Q.; Liang, H.-X.; Ding, Z.-H.; Liao, Z.-J.; Huang, G. HDAC6 promotes hepatocellular carcinoma progression by inhibiting p53 transcriptional activity. FEBS Lett. 2013, 587, 880–886.
110. Langley, E.; Pearson, M.; Faretta, M.; Bauer, U.M.; Frye, R.A.; Minucci, S.; Pelicci, P.G.; Kouzarides, T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21, 2383–2396.
111. Zhao, W.; Kruse, J.-P.; Tang, Y.; Jung, S.Y.; Qin, J.; Gu, W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature2008, 451, 587–590.
112. Kim, J.-E.; Chen, J.; Lou, Z. DBC1 is a negative regulator of SIRT1. Nature2008, 451, 583–586.
113. Kim, E.-J.; Kho, J.-H.; Kang, M.-R.; Um, S.-J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell2007, 28, 277–290.
114. Lain, S.; Hollick, J.J.; Campbell, J.; Staples, O.D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K.E.; Baker, L.; et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell2008, 13, 454–463.
115. Wang, R.-H.; Sengupta, K.; Li, C.; Kim, H.-S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell2008, 14, 312–323.
116. Cheng, H.-L.; Mostoslavsky, R.; Saito, S.I.; Manis, J.P.; Gu, Y.; Patel, P.; Bronson, R.; Appella, E.; Alt, F.W.; Chua, K.F. Developmental defects and p53 hyperacetylation in SIR2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA2003, 100, 10794–10799.
117. Chua, K.F.; Mostoslavsky, R.; Lombard, D.B.; Pang, W.W.; Saito, S.; Franco, S.; Kaushal, D.; Cheng, H.L.; Fischer, M.R.; Stokes, N.; et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell MeTable2005, 2, 67–76.
118. Fan, W.; Luo, J. SIRT1 regulates uv-induced DNA repair through deacetylating XPA. Mol. Cell2010, 39, 247–258.
119. Yuan, Z.; Zhang, X.; Sengupta, N.; Lane, W.S.; Seto, E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell2007, 27, 149–162.
120. Li, K.; Casta, A.; Wang, R.; Lozada, E.; Fan, W.; Kane, S.; Ge, Q.; Gu, W.; Orren, D.; Luo, J. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J. Biol. Chem. 2008, 283, 7590–7598.
121. Wu, X.; Bayle, J.H.; Olson, D.; Levine, A.J. The p53-Mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7, 1126–1132.
122. Picksley, S.M.; Lane, D.P. The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth-control by p53. Bioessays1993, 15, 689–690.
123. Kubbutat, M.H.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature1997, 387, 299–303.
124. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein Mdm2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25–27.
125. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature1997, 387, 296–299.
126. Marine, J.C.; Jochemsen, A.G. MdmX as an essential regulator of p53 activity. Biochem. Biophys. Res. Comm. 2005, 331, 750–760.
127. Jones, S.N.; Roe, A.E.; Donehower, L.A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature1995, 378, 206–208.
128. Montes de Oca Luna, R.; Wagner, D.S.; Lozano, G. Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature1995, 378, 203–206.
129. Parant, J.; Chavez-Reyes, A.; Little, N.A.; Yan, W.; Reinke, V.; Jochemsen, A.G.; Lozano, G. Rescue of embryonic lethality in Mdm4-null mice by loss of TRP53 suggests a nonoverlapping pathway with Mdm2 to regulate p53. Nat. Genet. 2001, 29, 92–95.
130. Barboza, J.A.; Iwakuma, T.; Terzian, T.; El-Naggar, A.K.; Lozano, G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol. Cancer Res. 2008, 6, 947–954.
131. Jain, A.K.; Barton, M.C. Making sense of ubiquitin ligases that regulate p53. Cancer Biol. Ther. 2010, 10, 665–672.
132. Li, M.Y.; Brooks, C.L.; Wu-Baer, F.; Chen, D.L.; Baer, R.; Gu, W. Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2. Science2003, 302, 1972–1975.
133. Lohrum, M.A.E.; Woods, D.B.; Ludwig, R.L.; Balint, E.; Vousden, K.H. C-Terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 2001, 21, 8521–8532.
134. Brooks, C.L.; Li, M.; Gu, W. Mechanistic studies of Mdm2-mediated ubiquitination in p53 regulation. J. Biol. Chem. 2007, 282, 22804–22815.
135. Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.; Pancoska, P.; Moll, U.M. p53 Has a direct apoptogenic role at the mitochondria. Mol. Cell2003, 11, 577–590.
136. Chipuk, J.E.; Kuwana, T.; Bouchier-Hayes, L.; Droin, N.M.; Newmeyer, D.; Schuler, M.; Green, D.R. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science2004, 303, 1010–1014.
137. Feng, Z.; Zhang, H.; Levine, A.J.; Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA2005, 102, 8204–8209.
138. Tasdemir, E.; Maiuri, M.C.; Galluzzi, L.; Vitale, I.; Djavaheri-Mergny, M.; D’Amelio, M.; Criollo, A.; Morselli, E.; Zhu, C.; Harper, F.; et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10, 676–687.
139. Kobet, E.; Zeng, X.Y.; Zhu, Y.; Keller, D.; Lu, H. Mdm2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA2000, 97, 12547–12552.
140. Wadgaonkar, R.; Collins, T. Murine double minute (Mdm2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 1999, 274, 13760–13767.
141. Ferreon, J.C.; Lee, C.W.; Arai, M.; Martinez-Yamout, M.A.; Dyson, H.J.; Wright, P.E. Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and Hdm2. Proc. Natl. Acad. Sci. USA2009, 106, 6591–6596.
142. Jin, Y.T.; Zeng, S.X.; Dai, M.S.; Yang, X.J.; Lu, H. Mdm2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 2002, 277, 30838–30843.
143. Nakamura, S.; Roth, J.A.; Mukhopadhyay, T. Multiple lysine mutations in the C-terminal domain of p53 interfere with Mdm2-dependent protein degradation and ubiquitination. Mol. Cell. Biol. 2000, 20, 9391–9398.
144. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Lane, D.P.; Hay, R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 2000, 20, 8458–8467.
145. Le Cam, L.; Linares, L.K.; Paul, C.; Julien, E.; Lacroix, M.; Hatchi, E.; Triboulet, R.; Bossis, G.; Shmueli, A.; Rodriguez, M.S.; et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell2006, 127, 775–788.
146. Shi, D.; Pop, M.S.; Kulikov, R.; Love, I.M.; Kung, A.; Grossman, S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. USA2009, 106, 16275–16280.
147. Grossman, S.R.; Deato, M.E.; Brignone, C.; Chan, H.M.; Kung, A.L.; Tagami, H.; Nakatani, Y.; Livingston, D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science2003, 300, 342–344.
148. Linares, L.K.; Kiernan, R.; Triboulet, R.; Chable-Bessia, C.; Latreille, D.; Cuvier, O.; Lacroix, M.; Le Cam, L.; Coux, O.; Benkirane, M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Mdm2. Nat. Cell Biol. 2007, 9, 331–338.
149. Banin, S.; Moyal, L.; Shieh, S.Y.; Taya, Y.; Anderson, C.W.; Chessa, L.; Smorodinsky, N.I.; Prives, C.; Reiss, Y.; Shiloh, Y.; et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science1998, 281, 1674–1677.
150. Canman, C.E.; Lim, D.S.; Cimprich, K.A.; Taya, Y.; Tamai, K.; Sakaguchi, K.; Appella, E.; Kastan, M.B.; Siliciano, J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science1998, 281, 1677–1679.
151. Leesmiller, S.P.; Sakaguchi, K.; Ullrich, S.J.; Appella, E.; Anderson, C.W. Human DNA-activated protein-kinase phosphorylates serine-15 and serine-37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 1992, 12, 5041–5049.
152. Shieh, S.Y.; Ikeda, M.; Taya, Y.; Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by Mdm2. Cell1997, 91, 325–334.
153. Siliciano, J.D.; Canman, C.E.; Taya, Y.; Sakaguchi, K.; Appella, E.; Kastan, M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997, 11, 3471–3481.
154. Tibbetts, R.S.; Brumbaugh, K.M.; Williams, J.M.; Sarkaria, J.N.; Cliby, W.A.; Shieh, S.Y.; Taya, Y.; Prives, C.; Abraham, R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999, 13, 152–157.
155. Khanna, K.K.; Keating, K.E.; Kozlov, S.; Scott, S.; Gatei, M.; Hobson, K.; Taya, Y.; Gabrielli, B.; Chan, D.; Lees-Miller, S.P.; et al. ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat. Genet. 1998, 20, 398–400.
156. Chehab, N.H.; Malikzay, A.; Appel, M.; Halazonetis, T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000, 14, 278–288.
157. Shieh, S.Y.; Ahn, J.; Tamai, K.; Taya, Y.; Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000, 14, 289–300.
158. Dumaz, N.; Milne, D.M.; Jardine, L.J.; Meek, D.W. Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem. J. 2001, 359, 459–464.
159. Unger, T.; Juven-Gershon, T.; Moallem, E.; Berger, M.; Vogt Sionov, R.; Lozano, G.; Oren, M.; Haupt, Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999, 18, 1805–1814.
160. D’Orazi, G.; Cecchinelli, B.; Bruno, T.; Manni, I.; Higashimoto, Y.; Saito, S.; Gostissa, M.; Coen, S.; Marchetti, A.; del Sal, G.; et al.Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 2002, 4, 11–19.
161. Hofmann, T.G.; Moller, A.; Sirma, H.; Zentgraf, H.; Taya, Y.; Droge, W.; Will, H.; Schmitz, M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 2002, 4, 1–10.
162. Ko, L.J.; Shieh, S.Y.; Chen, X.; Jayaraman, L.; Tamai, K.; Taya, Y.; Prives, C.; Pan, Z.Q. p53 Is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol. Cell. Biol. 1997, 17, 7220–7229.
163. Teufel, D.P.; Bycroft, M.; Fersht, A.R. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene2009, 28, 2112–2118.
164. Lee, C.W.; Ferreon, J.C.; Ferreon, A.C.M.; Arai, M.; Wright, P.E. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc. Natl. Acad. Sci. USA2010, 107, 19290–19295.
165. Jenkins, L.M.M.; Yamaguchi, H.; Hayashi, R.; Cherry, S.; Tropea, J.E.; Miller, M.; Wlodawer, A.; Appella, E.; Mazur, S.J. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry2009, 48, 1244–1255.
166. Kar, S.; Sakaguchi, K.; Shimohigashi, Y.; Samaddar, S.; Banerjee, R.; Basu, G.; Swaminathan, V.; Kundu, T.K.; Roy, S. Effect of phosphorylation on the structure and fold of transactivation domain of p53. J. Biol. Chem. 2002, 277, 15579–15585.
167. Lambert, P.F.; Kashanchi, F.; Radonovich, M.F.; Shiekhattar, R.; Brady, J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 1998, 273, 33048–33053.
168. Dumaz, N.; Meek, D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with Hdm2. EMBO J. 1999, 18, 7002–7010.
169. Lakin, N.D.; Jackson, S.P. Regulation of p53 in response to DNA damage. Oncogene1999, 18, 7644–7655.
170. Lee, C.W.; Arai, M.; Martinez-Yamout, M.A.; Dyson, H.J.; Wright, P.E. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry2009, 48, 2115–2124.
171. Saito, S.; Goodarzi, A.A.; Higashimoto, Y.; Noda, Y.; Lees-Miller, S.P.; Appella, E.; Anderson, C.W. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J. Biol. Chem. 2002, 277, 12491–12494.
172. Puca, R.; Nardinocchi, L.; Sacchi, A.; Rechavi, G.; Givol, D.; D’Orazi, G. HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol. Cancer2009, doi:10.1186/1476-4598-8-85.
173. Chao, C.; Saito, S.; Anderson, C.W.; Appella, E.; Xu, Y. Phosphorylation of murine p53 at Ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA2000, 97, 11936–11941.
174. Ou, Y.H.; Chung, P.H.; Sun, T.P.; Shieh, S.Y. p53 C-terminal phosphorylation by CHM and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol. Biol. Cell2005, 16, 1684–1695.
175. Kurash, J.K.; Lei, H.; Shen, Q.; Marston, W.L.; Granda, B.W.; Fan, H.; Wall, D.; Li, E.; Gaudet, F. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol. Cell2008, 29, 392–400.
176. Huang, J.; Perez-Burgos, L.; Placek, B.J.; Sengupta, R.; Richter, M.; Dorsey, J.A.; Kubicek, S.; Opravil, S.; Jenuwein, T.; Berger, S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature2006, 444, 629–632.
177. Ivanov, G.S.; Ivanova, T.; Kurash, J.; Ivanov, A.; Chuikov, S.; Gizatullin, F.; Herrera-Medina, E.M.; Rauscher, F., III; Reinberg, D.; Barlev, N.A. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol. Cell. Biol. 2007, 27, 6756–6769.
178. Shi, X.; Kachirskaia, L.; Yamaguchi, H.; West, L.E.; Wen, H.; Wang, E.W.; Dutta, S.; Appella, E.; Gozani, O. Modulation of p53 function by Set8-mediated methylation at lysine 382. Mol. Cell2007, 27, 636–646.
179. Chuikov, S.; Kurash, J.K.; Wilson, J.R.; Xiao, B.; Justin, N.; Ivanov, G.S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S.J.; et al. Regulation of p53 activity through lysine methylation. Nature2004, 432, 353–360.
180. Campaner, S.; Spreafico, F.; Burgold, T.; Doni, M.; Rosato, U.; Amati, B.; Testa, G. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol. Cell2011, 43, 681–688.
181. Lehnertz, B.; Rogalski, J.C.; Schulze, F.M.; Yi, L.; Lin, S.; Kast, J.; Rossi, F.M.V. p53-Dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol. Cell2011, 43, 673–680.
182. Gostissa, M.; Hengstermann, A.; Fogal, V.; Sandy, P.; Schwarz, S.E.; Scheffner, M.; del Sal, G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 1999, 18, 6462–6471.
183. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Midgley, C.A.; Lane, D.P.; Hay, R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 1999, 18, 6455–6461.
184. Fogal, V.; Gostissa, M.; Sandy, P.; Zacchi, P.; Sternsdorf, T.; Jensen, K.; Pandolfi, P.P.; Will, H.; Schneider, C.; del Sal, G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 2000, 19, 6185–6195.
185. Kwek, S.S.S.; Derry, J.; Tyner, A.L.; Shen, Z.Y.; Gudkov, A.V. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene2001, 20, 2587–2599.
186. Carter, S.; Bischof, O.; Dejean, A.; Vousden, K.H. C-Terminal modifications regulate Mdm2 dissociation and nuclear export of p53. Nat. Cell Biol. 2007, 9, 428–435.
187. Naidu, S.R.; Lakhter, A.J.; Androphy, E.J. PIASy-mediated Tip60 sumoylation regulates p53-induced autophagy. Cell Cycle2012, 11, 2717–2728.
188. Hay, R.T. SUMO: A history of modification. Mol. Cell2005, 18, 1–12.
189. Wu, S.-Y.; Chiang, C.-M. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 2009, 28, 1246–1259.
190. Abida, W.M.; Nikolaev, A.; Zhao, W.; Zhang, W.; Gu, W. FBXO11 promotes the neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 2007, 282, 1797–1804.
191. Shiseki, M.; Nagashima, M.; Pedeux, R.M.; Kitahama-Shiseki, M.; Miura, K.; Okamura, S.; Onogi, H.; Higashimoto, Y.; Appella, E.; Yokota, J.; et al. p29ING4 And p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003, 63, 2373–2378.
192. Pedeux, R.; Sengupta, S.; Shen, J.C.; Demidov, O.N.; Saito, S.; Onogi, H.; Kumamoto, K.; Wincovitch, S.; Garfield, S.H.; McMenamin, M.; et al. ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol. Cell. Biol. 2005, 25, 6639–6648.
193. Nagashima, M.; Shiseki, M.; Miura, K.; Hagiwara, K.; Linke, S.P.; Pedeux, R.; Wang, X.W.; Yokota, J.; Riabowol, K.; Harris, C.C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA2001, 98, 9671–9676.
194. Song, L.; Gao, M.; Dong, W.; Hu, M.; Li, J.; Shi, X.; Hao, Y.; Li, Y.; Huang, C. p85 Alpha mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response. Oncogene2011, 30, 1360–1371.
195. Dornan, D.; Eckert, M.; Wallace, M.; Shimizu, H.; Ramsay, E.; Hupp, T.R.; Ball, K.L. Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol. Cell. Biol. 2004, 24, 10083–10098.
196. Kim, W.J.; Rivera, M.N.; Coffman, E.J.; Haber, D.A. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol. Cell2012, 45, 587–597.
197. Pan, X.; Zhao, J.; Zhang, W.-N.; Li, H.-Y.; Mu, R.; Zhou, T.; Zhang, H.-Y.; Gong, W.-L.; Yu, M.; Man, J.-H.; et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc. Natl. Acad. Sci. USA2009, 106, 3788–3793.
198. Basbous, J.; Knani, D.; Bonneaud, N.; Giorgi, D.; Brondello, J.-M.; Rouquier, S. Induction of ASAP (MAP9) contributes to p53 stabilization in response to DNA damage. Cell Cycle2012, 11, 2380–2390.
199. Cui, D.; Li, L.; Lou, H.; Sun, H.; Ngai, S.-M.; Shao, G.; Tang, J. The ribosomal protein S26 regulates p53 activity in response to DNA damage. Oncogene2014, 33, 2225–2235.
200. Aikawa, Y.; Nguyen, L.A.; Isono, K.; Takakura, N.; Tagata, Y.; Schmitz, M.L.; Koseki, H.; Kitabayashi, I. Roles of HIPK1 and HIPK2 in AML1-and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J.2006, 25, 3955–3965.
201. Sabbatini, P.; McCormick, F. MdmX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 2002, 21, 519–525.
202. Grishina, I.; Debus, K.; Garcia-Limones, C.; Schneider, C.; Shresta, A.; Garcia, C.; Calzado, M.A.; Schmitz, M.L. SIAH-mediated ubiquitination and degradation of acetyl-transferases regulate the p53 response and protein acetylation. Biochim. Biophys. Acta2012, 1823, 2287–2296.
203. Scheffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, P.M. The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of p53. Cell1990, 63, 1129–1136.
204. Patel, D.; Huang, S.M.; Baglia, L.A.; McCance, D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J.1999, 18, 5061–5072.
205. Zimmermann, H.; Degenkolbe, R.; Bernard, H.U.; O’Connor, M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 1999, 73, 6209–6219.
206. Chakravarti, D.; Ogryzko, V.; Kao, H.Y.; Nash, A.; Chen, H.W.; Nakatani, Y.; Evans, R.M. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell1999, 96, 393–403.
207. Kitagawa, M.; Lee, S.H.; McCormick, F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol. Cell2008, 29, 217–231.
208. Gronroos, E.; Terentiev, A.A.; Punga, T.; Ericsson, J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc. Natl. Acad. Sci. USA2004, 101, 12165–12170.
209. Graczyk, A.; Slomnicki, L.P.; Lesniak, W. S100A6 competes with the TAZ2 domain of p300 for binding to p53 and attenuates p53 acetylation. J. Mol. Biol. 2013, 425, 3488–3494.
210. Nakayama, K.I.; Nakayama, K. Ubiquitin ligases: Cell-cycle control and cancer. Nat. Rev. Cancer2006, 6, 369–381.
211. Zhu, Q.Z.; Wani, G.; Wani, M.A.; Wani, A.A. Human homologue of yeast rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. Cancer Res. 2001, 61, 64–70.
212. Kim, J.-Y.; Lee, K.-S.; Seol, J.-E.; Yu, K.; Chakravarti, D.; Seo, S.-B. Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity. Nuc. Acids Res. 2012, 40, 75–87.
213. Liu, Y.; Colosimo, A.L.; Yang, X.J.; Liao, D.Q. Adenovirus E1b 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell. Biol. 2000, 20, 5540–5553.
214. Avvakumov, N.; Torchia, J.; Mymryk, J.S. Interaction of the HPV E7 proteins with the PCAF acetyltransferase. Oncogene2003, 22, 3833–3841.
215. Jin, Y.T.; Zeng, S.X.; Lee, H.; Lu, H. Mdm2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J. Biol. Chem. 2004, 279, 20035–20043.
216. Di Stefano, V.; Soddu, S.; Sacchi, A.; D’Orazi, G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21(WAF1) after nonapoptotic DNA damage. Oncogene2005, 24, 5431–5442.
217. Sho, T.; Tsukiyama, T.; Sato, T.; Kondo, T.; Cheng, J.; Saku, T.; Asaka, M.; Hatakeyama, S. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim. Biophys. Acta2011, 1813, 1245–1253.
218. Dai, C.; Shi, D.; Gu, W. Negative regulation of the acetyltransferase Tip60-p53 interplay by UHRF1 (Ubiquitin-like with PHD and RING finger domains 1). J. Biol. Chem. 2013, 288, 19581–19592.
219. Xu, L.; Chen, Y.; Song, Q.; Xu, D.; Wang, Y.; Ma, D. PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia2009, 11, 345–354.
220. Dar, A.; Shibata, E.; Dutta, A. Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol. Cell. Biol. 2013, 33, 3309–3320.
221. Charvet, C.; Wissler, M.; Brauns-Schubert, P.; Wang, S.-J.; Tang, Y.; Sigloch, F.C.; Mellert, H.; Brandenburg, M.; Lindner, S.E.; Breit, B.; et al. Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol. Cell2011, 42, 584–596.
222. Dai, C.; Tang, Y.; Jung, S.Y.; Qin, J.; Aaronson, S.A.; Gu, W. Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc. Natl. Acad. Sci. USA2011, 108, 18937–18942.
223. Huang, J.; Yang, J.; Maity, B.; Mayuzumi, D.; Fisher, R.A. Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res. 2011, 71, 6310–6319.
224. Huang, J.; Stewart, A.; Maity, B.; Hagen, J.; Fagan, R.L.; Yang, J.; Quelle, D.E.; Brenner, C.; Fisher, R.A. RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated DNMT1 degradation and promoting apoptosis. Oncogene2013, doi:10.1038/onc.2013.324.
225. Sherr, C.J. Divorcing ARF and p53: An unsettled case. Nat. Rev. Cancer2006, 6, 663–673.
226. Eymin, B.; Claverie, P.; Salon, C.; Leduc, C.; Col, E.; Brambilla, E.; Khochbin, S.; Gazzeri, S. P14(ARF) activates a Tip60-dependent and p53-independent ATM/ATR/Chk pathway in response to genotoxic stress. Mol. Cell. Biol. 2006, 26, 4339–4350.
227. Tompkins, V.S.; Hagen, J.; Frazier, A.A.; Lushnikova, T.; Fitzgerald, M.P.; di Tommaso, A.; Ladeveze, V.; Domann, F.E.; Eischen, C.M.; Quelle, D.E. A novel nuclear interactor of ARF and Mdm2 (NIAM) that maintains chromosomal stability. J. Biol. Chem. 2007, 282, 1322–1333.
228. Reed, S.M.; Hagen, J.; Tompkins, V.; Thies, K.; Quelle, F.W.; Quelle, D.E. Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell Cycle2014, 13, 1288–1298.
229. Kitabayashi, I.; Yokoyama, A.; Shimizu, K.; Ohki, M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998, 17, 2994–3004.
230. Kung, A.L.; Rebel, V.I.; Bronson, R.T.; Ch’ng, L.E.; Sieff, C.A.; Livingston, D.M.; Yao, T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 2000, 14, 272–277.
231. Gayther, S.A.; Batley, S.J.; Linger, L.; Bannister, A.; Thorpe, K.; Chin, S.F.; Daigo, Y.; Russell, P.; Wilson, A.; Sowter, H.M.; et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24, 300–303.
232. Iyer, N.G.; Ozdag, H.; Caldas, C. P300/CBP and cancer. Oncogene2004, 23, 4225–4231.
233. Goodman, R.H.; Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14, 1553–1577.
234. Borrow, J.; Stanton, V.P.; Andresen, J.M.; Becher, R.; Behm, F.G.; Chaganti, R.S.K.; Civin, C.I.; Disteche, C.; Dube, I.; Frischauf, A.M.; et al. The translocation t(8;l6)(p11, p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB binding protein. Nat. Genet. 1996, 14, 33–41.
235. Muraoka, M.; Konishi, M.; KikuchiYanoshita, R.; Tanaka, K.; Shitara, N.; Chong, J.M.; Iwama, T.; Miyaki, M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene1996, 12, 1565–1569.
236. Perez, R.E.; Knights, C.D.; Sahu, G.; Catania, J.; Kolukula, V.K.; Stoler, D.; Graessmann, A.; Ogryzko, V.; Pishvaian, M.; Albanese, C.; et al. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J. Cell. Physiol. 2010, 225, 394–405.
237. Ying, M.-Z.; Wang, J.-J.; Li, D.-W.; Yu, G.-Z.; Wang, X.; Pan, J.; Chen, Y.; He, M.-X. The p300/CBP associated factor is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome. Cancer Biol. Ther. 2010, 9, 312–320.
238. Gorrini, C.; Squatrito, M.; Luise, C.; Syed, N.; Perna, D.; Wark, L.; Martinato, F.; Sardella, D.; Verrecchia, A.; Bennett, S.; et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature2007, 448, 1063–1067.
239. Lleonart, M.E.; Vidal, F.; Gallardo, D.; Diaz-Fuertes, M.; Rojo, F.; Cuatrecasas, M.; Lopez-Vicente, L.; Kondoh, H.; Blanco, C.; Carnero, A.; et al. New p53 related genes in human tumors: Significant downregulation in colon and lung carcinomas. Oncol. Reports2006, 16, 603–608.
240. Sakuraba, K.; Yokomizo, K.; Shirahata, A.; Goto, T.; Saito, M.; Ishibashi, K.; Kigawa, G.; Nemoto, H.; Hibi, K. Tip60 as a potential marker for the malignancy of gastric cancer. Anticancer Res. 2011, 31, 77–79.
241. Sakuraba, K.; Yasuda, T.; Sakata, M.; Kitamura, Y.-H.; Shirahata, A.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; et al. Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. Anticancer Res. 2009, 29, 3953–3955.
242. Zhao, H.; Jin, S.; Gewirtz, A.M. The histone acetyltransferase Tip60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia. J. Biol. Chem. 2012, 287, 925–934.
243. Chen, G.; Cheng, Y.; Tang, Y.; Martinka, M.; Li, G. Role of Tip60 in human melanoma cell migration, metastasis, and patient survival. J. Invest. Derm. 2012, 132, 2632–2641.
244. Huntly, B.J.P.; Shigematsu, H.; Deguchi, K.; Lee, B.H.; Mizuno, S.; Duclos, N.; Rowan, R.; Amaral, S.; Curley, D.; Williams, I.R.; et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell2004, 6, 587–596.
245. Deguchi, K.; Ayton, P.M.; Carapeti, M.; Kutok, J.L.; Snyder, C.S.; Williams, I.R.; Cross, N.C.P.; Glass, C.K.; Cleary, M.L.; Gilliland, D.G. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell2003, 3, 259–271.
246. Ida, K.; Kitabayashi, I.; Taki, T.; Taniwaki, M.; Noro, K.; Yamamoto, M.; Ohki, M.; Hayashi, Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood1997, 90, 4699–4704.
247. Sobulo, O.M.; Borrow, J.; Tomek, R.; Reshmi, S.; Harden, A.; Schlegelberger, B.; Housman, D.; Doggett, N.A.; Rowley, J.D.; ZeleznikLe, N.J. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. USA1997, 94, 8732–8737.
248. Gupta, A.; Sharma, G.G.; Young, C.S.H.; Agarwal, M.; Smith, E.R.; Paull, T.T.; Lucchesi, J.C.; Khanna, K.K.; Ludwig, T.; Pandita, T.K. Involvement of human MOF in ATM function. Mol. Cell. Biol. 2005, 25, 5292–5305.
249. Gupta, A.; Guerin-Peyrou, T.G.; Sharma, G.G.; Park, C.; Agarwal, M.; Ganju, R.K.; Pandita, S.; Choi, K.; Sukumar, S.; Pandita, R.K.; et al. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol. Cell. Biol. 2008, 28, 397–409.
250. Shogren-Knaak, M.; Ishii, H.; Sun, J.M.; Pazin, M.J.; Davie, J.R.; Peterson, C.L. Histone H4-k16 acetylation controls chromatin structure and protein interactions. Science2006, 311, 844–847.
251. Sapountzi, V.; Logan, I.R.; Robson, C.N. Cellular functions of Tip60. Int. J. Biochem. Cell Biol. 2006, 38, 1496–1509.
252. Henry, R.A.; Kuo, Y.-M.; Andrews, A.J. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4. Biochemistry2013, 52, 5746–5759.
253. Hu, Y.; Fisher, J.B.; Koprowski, S.; McAllister, D.; Kim, M.-S.; Lough, J. Homozygous disruption of the Tip60 gene causes early embryonic lethality. Develop. Dynamics2009, 238, 2912–2921.
254. Katsumoto, T.; Aikawa, Y.; Iwama, A.; Ueda, S.; Ichikawa, H.; Ochiya, T.; Kitabayashi, I. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 2006, 20, 1321–1330.
255. Yao, T.P.; Oh, S.P.; Fuchs, M.; Zhou, N.D.; Ch’ng, L.E.; Newsome, D.; Bronson, R.T.; Li, E.; Livingston, D.M.; Eckner, R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell1998, 93, 361–372.
256. Sah, V.P.; Attardi, L.D.; Mulligan, G.J.; Williams, B.O.; Bronson, R.T.; Jacks, T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 1995, 10, 175–180.
257. McKeller, R.N.; Fowler, J.L.; Cunningham, J.J.; Warner, N.; Smeyne, R.J.; Zindy, F.; Skapek, S.X. The ARF tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc. Natl. Acad. Sci. USA2002, 99, 3848–3853.
258. Reichel, M.B.; Ali, R.R.; D’Esposito, F.; Clarke, A.R.; Luthert, P.J.; Bhattacharya, S.S.; Hunt, D.M. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell Death Differ. 1998, 5, 156–162.
259. Ikeda, S.; Hawes, N.L.; Chang, B.; Avery, C.S.; Smith, R.S.; Nishina, P.M. Severe ocular abnormalities in C57BL/6 but not in 129/SV p53-deficient mice. Invest. Ophthalmol. Vis. Sci. 1999, 40, 1874–1878.
260. Gannon, H.S.; Jones, S.N. Using mouse models to explore Mdm-p53 signaling in development, cell growth, and tumorigenesis. Genes Cancer2012, 3, 209–218.
261. Li, T.; Kon, N.; Jiang, L.; Tan, M.; Ludwig, T.; Zhao, Y.; Baer, R.; Gu, W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell2012, 149, 1269–1283.
262. Christophorou, M.A.; Ringshausen, I.; Finch, A.J.; Swigart, L.B.; Evan, G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature2006, 443, 214–217.
263. Jiang, P.; Du, W.; Mancuso, A.; Wellen, K.E.; Yang, X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature2013, 493, 689–693.
264. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell2011, 144, 646–674.